Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life

Late-life depression (LLD) is a major depressive disorder that affects someone after the age of 60 years. LLD is frequently associated with inadequate response and remission from antidepressants, in addition to polypharmacy. Pharmacogenetics offers a promising approach to improve clinical outcomes i...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics 2018-11, Vol.19 (16), p.1269-1284
Main Authors: Chang, Donald D, Eyreeuro, Harris A, Abbott, Ryan, Coudreaut, Michael, Baune, Bernhard T, Shaman, Jeffrey A, Lavretsky, Helen, Lenze, Eric J, Merrill, David A, Singh, Ajeet B, Mulsant, Benoit H, Reynolds, Charles F, Müller, Daniel J, Bousman, Chad
Format: Article
Language:English
Subjects:
Aging
Antidepressants
Antidepressive Agents - therapeutic use
Census of Population
Clinical trials
Consortia
Cost analysis
decision support tools
Depression - drug therapy
Depressive Disorder, Major - drug therapy
Drug dosages
Geriatrics
Glycoproteins
Humans
late-life depression
major depression
Mental depression
Older people
Pharmacogenetics
Pharmacogenetics - standards
Pharmacogenomic Testing - standards
pharmacogenomics
Polypharmacy
precision medicine
Precision Medicine - standards
Prescription drugs
Psychiatry
Remission
Serotonin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Late-life depression (LLD) is a major depressive disorder that affects someone after the age of 60 years. LLD is frequently associated with inadequate response and remission from antidepressants, in addition to polypharmacy. Pharmacogenetics offers a promising approach to improve clinical outcomes in LLD via new discoveries determining the genetic basis of response rates and side effects, as well as the development of tailored pharmacogenetic-based decision support tools. This invited review evaluates the LLD pharmacogenetic evidence base and the extent to which this was incorporated into existing commercial decision support tools and clinical pharmacogenetic guidelines.
ISSN:1462-2416
1744-8042
DOI:10.2217/pgs-2018-0099